Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04169815 · ClinicalTrials.gov registry record
Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 2,370
- Enrollment target
NCT04169815: Completed study, sponsored by Beckman Coulter.
NCT04169815 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 2,370 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04169815 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 2,370 participants
- Enrollment target
Study Summary
The purpose of the pivotal study is to collect blood specimens and clinical data from patients suspected of having Heart Failure (HF), which will be tested at a future date on Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.
Primary Outcome
Establish the performance of the future Natriuretic Peptide assay(s) against the adjudicated diagnosis.
Interventions
- DIAGNOSTIC_TEST Access Immunodiagnostic Products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,370 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2022-09-30 |
What the finished NCT04169815 record still lists
NCT04169815 is an observational study that tracks outcomes without assigning an intervention. Its 2,370 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Access Immunodiagnostic Products is the first listed.
NCT04169815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04169815 about?
NCT04169815 is a clinical study titled "Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection". The purpose of the pivotal study is to collect blood specimens and clinical data from patients suspected of having Heart Failure (HF), which will be tested at a future date on Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.
What is the current status of trial NCT04169815?
This trial is currently completed. The enrollment target is 2,370 participants. The study started on 2019-11-20. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT04169815?
The interventions under investigation include: Access Immunodiagnostic Products (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04169815?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05868421 · 2,376 participants · NA
Veteran Social Support for Enhancing Use of Smoking Cessation Treatment
- NCT00025935 · 2,350 participants
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
- NCT03099850 · 2,345 participants
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
- NCT06747494 · 2,396 participants · NA
General vs Spinal in Total Joint Arthroplasty (TJA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI